[Immunocheckpoint inhibition in head and neck squamous cell carcinoma: the current status and progress].

Over the past decades, although the clinical efficacy of advanced head and neck squamous cell carcinoma (HNSCC) has been moderately improved by the combination of cetuximab and chemotherapy, no remarkable treatment has emerged. The prognosis of HNSCC is still unsatisfied. With the deeper exploration of tumor immunological therapy, immunocheckpoint inhibitors such as monoclonal antibodies targeting on programmed cell death protein 1 (PD-1)/ cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) have shown appreciable anti-tumor effect on cancers such as melanoma and non-small cell lung cancer. Some successful clinical studies on HNSCC have also been reported, which provide a new opportunity for the improvement of HNSCC prognosis.Here we systemically review the progress of checkpoint inhibitors and its combination therapy in HNSCC, some immunotherapy efficacy-related biomarkers are also discussed.虽然西妥昔单抗联合化疗使晚期头颈部鳞癌(HNSCC)的治疗效果有了提高，但仍然缺乏更有效的治疗突破，患者的预后不佳。随着人们对肿瘤免疫治疗认识的不断深入，程序性死亡蛋白1、细胞毒T淋巴细胞抗原4的单克隆抗体等免疫检查点抑制剂已在黑色素瘤和非小细胞肺癌等肿瘤的治疗中显示出有效的抗肿瘤作用，在HNSCC中也有一些成功的临床研究，为改善HNSCC患者的预后提供了新的机会。文章介绍了免疫检查点抑制剂及其联合方案治疗HNSCC的研究进展，并探讨了与其免疫治疗疗效相关的生物标志物。.